The groundbreaking success of Sildenafil undeniably revolutionized the drug landscape, but investing in companies strongly reliant on off-patent versions presents a challenging picture. Despite early profits were substantial, the end of patents and the appearance of cheaper alternatives have eroded sales. Therefore, a thorough assessment of present